Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday

Stoke Therapeutics (NASDAQ:STOK) is anticipated to post its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect Stoke Therapeutics to post earnings of ($0.56) per share and revenue of $6.06 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Stoke Therapeutics Stock Down 5.2%

Shares of STOK opened at $30.04 on Friday. The company has a 50-day moving average price of $26.02 and a two-hundred day moving average price of $16.67. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of 35.34 and a beta of 1.24. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69.

Insiders Place Their Bets

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total value of $750,000.00. Following the completion of the sale, the director owned 49,124 shares in the company, valued at approximately $1,473,720. This trade represents a 33.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 5,501 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the transaction, the insider owned 18,469 shares in the company, valued at $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 180,676 shares of company stock valued at $4,071,664 in the last 90 days. 9.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of STOK. Corient Private Wealth LLC bought a new stake in shares of Stoke Therapeutics during the second quarter worth $7,489,000. Goldman Sachs Group Inc. increased its position in Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the period. Opaleye Management Inc. raised its holdings in Stoke Therapeutics by 87.4% during the 2nd quarter. Opaleye Management Inc. now owns 562,120 shares of the company’s stock worth $6,380,000 after purchasing an additional 262,120 shares during the last quarter. MPM Bioimpact LLC lifted its position in Stoke Therapeutics by 13.8% during the 2nd quarter. MPM Bioimpact LLC now owns 789,698 shares of the company’s stock valued at $8,963,000 after purchasing an additional 95,710 shares during the period. Finally, Engineers Gate Manager LP bought a new position in shares of Stoke Therapeutics in the 2nd quarter valued at about $378,000.

Wall Street Analyst Weigh In

Several brokerages recently commented on STOK. Wedbush boosted their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, August 13th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They issued a “buy” rating and a $30.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, August 13th. BTIG Research lifted their price target on shares of Stoke Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a report on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.